Form 4: OptiNose CFO Terry Kohler Disposes of Shares and Options Following Merger with Paratek Pharmaceuticals
SEC Form 4
Following the merger of OptiNose with Paratek Pharmaceuticals, CFO Terry Kohler reports the disposal of common stock and stock options as part of the merger agreement.
Summary
- Terry Kohler, CFO of OptiNose, filed a Form 4 detailing changes in beneficial ownership following the merger with Paratek Pharmaceuticals.
- The merger, effective May 21, 2025, resulted in the disposal of 30,541 shares of common stock.
- Kohler also disposed of stock options with exercise prices of $10.65 (45,000 options) and $5.77 (6,950 options).
- The merger agreement stipulated that common stock was converted into the right to receive $9.00 in cash and one contingent value right (CVR) per share.
- Vested restricted stock units (RSUs) were canceled, with holders receiving cash consideration and one CVR per share.
- Unvested RSUs were canceled, with holders contingently entitled to receive cash consideration and one CVR per share, vesting at the same time as the original RSUs.
- Stock options were converted into the right to receive cash equal to the excess of $9.00 over the exercise price, or a CVR if the exercise price was between $9.00 and $14.00.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing related to a merger. It's neutral in tone and simply reports the changes in beneficial ownership. The merger itself could be viewed as positive or negative depending on the investor's perspective, but the filing itself is neither.
Future Outlook
The document outlines the financial implications for Terry Kohler, CFO, following the merger of OptiNose with Paratek Pharmaceuticals, including the conversion of stock and options into cash and contingent value rights.
Industry Context
This announcement reflects a common scenario following a merger or acquisition, where executives and major shareholders adjust their holdings in accordance with the terms of the agreement. It's typical for stock options and shares to be converted into cash, new equity, or contingent rights.
Stakeholder Impact
- Shareholders received $9.00 in cash and one CVR per share.
- Employees with RSUs and stock options were affected by the conversion terms outlined in the merger agreement.
Key Dates
| Date | Description |
|---|---|
| 03/19/2025 | Issuer entered into an Agreement and Plan of Merger with Paratek Pharmaceuticals, Inc. |
| 05/21/2025 | Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the 'Effective Time'). |
| 05/21/2025 | Date of earliest transaction reported (disposal of shares and options). |
| 10/07/2034 | Expiration date of one set of stock options. |
| 02/21/2035 | Expiration date of another set of stock options. |
Keywords
Form 4, OptiNose, Paratek Pharmaceuticals, Merger, CFO, Terry Kohler, Beneficial Ownership, Stock Options, Common Stock, Contingent Value Right, CVR
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.